# Isomorphic Labs’ $2.1B Series B: AI Drug Design Gets Sovereign-Scale Capital

Times of AI Desk · 2026-05-12 · Industry

[https://timesof.ai/2026/05/isomorphic-labs-raises-2-1-billion-series-b-ai-drug-design](https://timesof.ai/2026/05/isomorphic-labs-raises-2-1-billion-series-b-ai-drug-design)

> DeepMind spinout Isomorphic Labs raises $2.1B Series B led by Thrive, with Alphabet, GV, MGX, Temasek, CapitalG, and the UK Sovereign AI Fund — to scale IsoDDE and advance pipeline toward clinic. Conviction capital for AI-native drug design; clinical proof is still ahead of the financing.

AI drug-design stories often stop at structure prediction. A **$2.1B** round with sovereign and hyperscaler capital is a bet that IsoDDE can compress the path **toward clinical candidates** — financing conviction ahead of clinical proof.

**Isomorphic Labs** (May 12), the AI-first drug design company spun out of Google DeepMind, announced a **$2.1 billion Series B** led by **Thrive Capital**, with Alphabet, GV, **MGX**, **Temasek**, CapitalG, and the **UK Sovereign AI Fund**. Proceeds: scale the **IsoDDE** platform, expand global operations (London, Cambridge, and other hubs), and advance therapeutic candidates toward clinical trials across modalities.

## Round and platform

- **Amount**: $2.1B Series B.
- **Lead**: Thrive Capital; participants include Alphabet, GV (existing), MGX, Temasek, CapitalG, UK Sovereign AI Fund (new).
- **Tech**: IsoDDE — unified AI system for biomolecular structures, binding affinities, and novel candidates (small molecules, biologics, antibodies); builds on AlphaFold-lineage work.
- **Pipeline focus**: Oncology and immunology among internal areas; biopharma partnerships cited.

Leadership quotes (Hassabis; Ruth Porat) frame confidence in AI-first healthcare timelines — **company and investor statements**.

## Claims vs checks

Round size and investor list are **Isomorphic Labs primary** (PR Newswire; Bloomberg / Fierce Biotech confirmation). Clinical acceleration claims are **aspirational** until trial readouts. Prior ~$600M external round context is company history, not this round’s diligence package.

## Limits

- Capital ≠ approved drugs.
- IsoDDE performance vs traditional discovery timelines is not independently audited in the raise announcement.
- Sovereign fund participation is strategic interest, not regulatory endorsement.

## Sources

- [Isomorphic Labs Series B announcement](https://isomorphiclabs.com/articles/isomorphic-labs-announces-series-b-investment-round) (May 12, 2026).
- PR Newswire (May 12, 2026).
- Bloomberg and Fierce Biotech coverage (May 12, 2026).